The dream of a disease free world

Our approach with MyCART aims to treat a variety of cancers by redesigning patients’ own immune cells to fight them.

Cancer is a disease caused due to a mutation in the DNA within cells that causes them to multiply at an abnormal rate and is one of the leading causes of death in the world.

Current Line of Treatment



Monoclonal Antibodies
  • High chance of reoccurrence
  • Long duration therapy


  • Not targeted
  • Serious side effects
  • Painful


  • Invasive
  • Selective use cases

Significant Worldwide Burden

Annual Cases


4.90 m

MyCART is an advanced autologous CAR T-cell therapy where your own T cells are redesigned to fight cancer cells. In MyCART, your T cells are genetically engineered to produce an artificial T cell receptor or CAR (Chimeric Antigen Receptor). The CAR is an antibody fragment that is directed against the unique receptors found on cancer cells. This rational design allows the CAR T-cells to specifically recognise cancer cells and effectively destroy them in the process. Furthermore, besides providing robust anti-tumour activity, CAR T-cells also persist for long periods of time in turn reducing risk of relapse.

MyCART is being designed and developed for patients with blood cancer (B-cell Lymphoma, Leukemia and Multiple Myeloma), lung cancer and prostate cancer.

Check out some of the other next-generation living therapeutics that are being developed by Micro CRISPR.